Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study.

PURPOSE We investigated the impact of Hodgkin lymphoma (HL) on parenthood, including factors influencing parenthood probability, by comparing long-term HL survivors with matched general population controls. PATIENTS AND METHODS A Life Situation Questionnaire was sent to 3,604 survivors treated from 1964 to 2004 in successive clinical trials. Responders were matched with controls (1:3 or 4) for sex, country, education, and year of birth (10-year groups). Controls were given an artificial date of start of treatment equal to that of their matched case. The main end point was presence of biologic children after treatment, which was evaluated by using conditional logistic regression analysis. Logistic regression analysis was used to analyze factors influencing spontaneous post-treatment parenthood. RESULTS In all, 1,654 French and Dutch survivors were matched with 6,414 controls. Median follow-up was 14 years (range, 5 to 44 years). After treatment, the odds ratio (OR) for having children was 0.77 (95% CI, 0.68 to 0.87; P < .001) for survivors compared with controls. Of 898 survivors who were childless before treatment, 46.7% achieved post-treatment parenthood compared with 49.3% of 3,196 childless controls (OR, 0.87; P = .08). Among 756 survivors with children before treatment, 12.4% became parents after HL treatment compared with 22.2% of 3,218 controls with children before treatment (OR, 0.49; P < .001). Treatment with alkylating agents, second-line therapy, and age older than 35 years at treatment appeared to reduce the chances of spontaneous post-treatment parenthood. CONCLUSION Survivors of HL had slightly but significantly fewer children after treatment than matched general population controls. The difference concerned only survivors who had children before treatment and appears to have more personal than biologic reasons. The chance of successful post-treatment parenthood was 76%.

[1]  S. Fosså,et al.  Pregnancy after adolescent and adult cancer: A population‐based matched cohort study , 2011, International journal of cancer.

[2]  P. Pisani,et al.  Marriage and parenthood among childhood cancer survivors: a report from the Italian AIEOP Off-Therapy Registry , 2011, Haematologica.

[3]  D. Green,et al.  Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Fosså,et al.  Do male lymphoma survivors have impaired sexual function? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Severson,et al.  Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis. , 2009, Archives of pediatrics & adolescent medicine.

[6]  P. Neven,et al.  Reproduction rates after cytotoxic therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Green,et al.  Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Fosså,et al.  Reproduction rates after cancer treatment: experience from the Norwegian radium hospital. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Sankila,et al.  Probability of parenthood after early onset cancer: A population‐based study , 2008, International journal of cancer.

[10]  A. Syse Does cancer affect marriage rates? , 2008, Journal of cancer survivorship : research and practice.

[11]  J. Raemaekers,et al.  Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. , 2007, The New England journal of medicine.

[12]  S. Tretli,et al.  Parenthood after cancer—a population‐based study , 2007, Psycho-oncology.

[13]  M. Zeegers,et al.  Offspring sex ratio and gonadal irradiation in the British Childhood Cancer Survivor Study , 2007, British Journal of Cancer.

[14]  S. Fosså,et al.  Post-treatment parenthood in Hodgkin's lymphoma survivors , 2007, British Journal of Cancer.

[15]  R. Tsang,et al.  Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy , 2007, Hematological oncology.

[16]  M. Vignetti,et al.  Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. , 2007, Haematologica.

[17]  J. Raemaekers,et al.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Hamilton,et al.  Trend analysis of the sex ratio at birth in the United States. , 2005, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[19]  E. Noordijk,et al.  First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL) , 2005 .

[20]  J. Raemaekers,et al.  Involved-field radiotherapy for advanced Hodgkin's lymphoma. , 2003, The New England journal of medicine.

[21]  D. Green,et al.  Pregnancy outcome of partners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Thomsen,et al.  Sex ratio among offspring of childhood cancer survivors treated with radiotherapy , 2003, British Journal of Cancer.

[23]  L. Schover,et al.  Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Raemaekers,et al.  The achievements of the EORTC Lymphoma Group , 2002 .

[25]  M. Glabbeke,et al.  The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. , 2002, European journal of cancer.

[26]  L. Toulemon Combien d’enfants, combien de frères et sœurs depuis cent ans ? , 2001, Population &amp; Sociétés.

[27]  J. Radford,et al.  Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Davis,et al.  Reduced ratio of male to female births in several industrial countries: a sentinel health indicator? , 1998, JAMA.

[29]  P. Boyle,et al.  The increase of Hodgkin's disease incidence among young adults , 1997, Cancer.

[30]  K. Jöckel,et al.  Change in male proportion among newborn infants , 1997, The Lancet.

[31]  V. Diehl,et al.  BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  A. Hagenbeek,et al.  A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Hagenbeek,et al.  Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Aisner,et al.  Pregnancy outcome in patients treated for Hodgkin's disease. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  E. Noordijk,et al.  Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Connors,et al.  MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Tubiana,et al.  Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease. , 1981, European journal of cancer.

[38]  M. Tubiana,et al.  Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease. , 1979, European journal of cancer.

[39]  F. Wilner,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1975, Michigan medicine.

[40]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.

[41]  V. Devita,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1970, Annals of internal medicine.

[42]  P. Marynen,et al.  The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. , 2007, Haematologica.

[43]  W. James Offspring sex ratios at birth as markers of paternal endocrine disruption. , 2006, Environmental research.

[44]  V. Diehl,et al.  Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study Group. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  A. Audebert,et al.  [The combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP) before radiotherapy in localized stages of Hodgkin's disease. Phase II trials]. , 1987, Bulletin du cancer.